AACC Notes-Diagnostic Stocks and Rayno Model Portfolio

Here are some brief notes from our visit to the AACC in Anaheim and recent earnings reports.

buy Lyrica in mexico Rayno Diagnostic and Tools Portfolio

can you buy prednisone over the counter Abaxis (ABAX)-under review– and Quidel (QDEL) report today.We added Quidel to our model portfolio on 6/16 at $12.40.The stock is trading at around $12 maybe anticipating dilution due to the $130M acquisition of Diagnostic Hybrids which has sales of $38M. Abaxis is looking attractive at this price $18 and a PEG ratio of 1.15.so earnings will be closely watched.

follow site Iris(IRIS)-stock under review announced the $4.7M cash acquisition of a high complexity 10.000 sq ft CLIA certified laboratory. The acquisition will be dilutive to earnings in 2010 and 2011 estimated at -$0.09 -$0.11 per share. The laboratory does nor currently have revenue and one strategy is to leverage its NADiA platform technology to perform a prognostic prostate cancer test which is pending FDA clearance. Selling clinical tests through a central lab is a major strategy shift for IRIS as  their product sales growth is slowing and the stock is at a two year low under $10. The P/S ratio is about 1.7 with recent earnings of $0.03 in the current quarter. Expect other strategic actions from IRIS, maybe another acquisition.

Alera (ALR) formerly Inverness IMA. Reported earnings yesterday and the stock is up 2% to $28.25 but off its all time high near 40.Q2 Revenues were $523M compared to $438.7 of one year ago. Acquisitions contributed $62.5M in incremental revenues. North American Influenza sales took a big hit down to $0.6M compared to $14.6 M one year ago. GAAP Net Loss was $0.10 per share compared to $0.01 for Q2 2009. Long Term Debt is over $2B with Shareholder Equity of about $3.5B. The PEG ratio based on future forecasts is 0.73.

MicroFluidics (MFLU.OB).We added MicroFluidics to our portfolio on 7/6 at $0.77. The stock does not trade in any significant volume presumably due to the Abraxis deal and stock owned by insiders and 5% shareholders. Market Cap is under $10M.

The stock is very hard to buy in any volume under $1.00 and the bid/ask spread is wider than ever like $0.53/.0.90.

Neogen(NEOG)-we added Neogen to our portfolio on 7/2 and it is up 12.8% since that time.

Other companies in our coverage universe that will be reporting in the days ahead are : Celera(CRA) ,GenProbe (GPRO) and Seracare (SRLS).

NEXT: Biomarkers for Cardiovascular Prevention:Plenary Session for AACC

No comments yet.

Leave a Reply